Efficacy and safety of posaconazole in prevention of invasive fungal infections during allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis

Yanfang ZHANG; Shifeng LOU; Shu CHEN; Kang ZHOU; Yun LUO; Xi HUANG; Jianchuan DENG

doi:10.16016/j.1000-5404.202108062

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of posaconazole in prevention of invasive fungal infections during allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis

Monographic Reports: Basic and clinical research on complications after hematopoietic stem cell transplantation | 更新时间：2026-02-13

- Efficacy and safety of posaconazole in prevention of invasive fungal infections during allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis
- Journal of Third Military Medical University Vol. 43, Issue 21, Pages: 2307-2312(2021)
- 作者机构：
  
  400010 重庆，重庆医科大学附属第二医院血液内科
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.202108062
  CLC： R519;R617;R978.5
- Received：10 August 2021，
  
  Revised：2021-09-01，
  
  Published：15 November 2021
- 稿件说明：
移动端阅览
Yanfang ZHANG, Shifeng LOU, Shu CHEN, et al. Efficacy and safety of posaconazole in prevention of invasive fungal infections during allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis[J]. Journal of Third Military Medical University, 2021, 43(21): 2307-2312.
DOI：

Yanfang ZHANG, Shifeng LOU, Shu CHEN, et al. Efficacy and safety of posaconazole in prevention of invasive fungal infections during allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis[J]. Journal of Third Military Medical University, 2021, 43(21): 2307-2312. DOI： 10.16016/j.1000-5404.202108062.

摘要

目的

探讨泊沙康唑(posaconazole，PCZ)在异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation

allo-HSCT)期间预防侵袭性真菌病(invasive fungal disease

IFD)的效果和安全性。

方法

回顾性分析2017年3月至2021年3月本院进行allo-HSCT的80例患者资料，观察移植期间接受泊沙康唑(泊沙康唑组，

=50)和同期接受其他抗真菌药物(对照组，

=30)预防IFD的效果和安全性。

结果

泊沙康唑组6例(12.0%)发生IFD，其中确诊2例，临床诊断4例。对照组14例(46.7%)发生IFD，其中确诊6例，临床诊断6例，拟诊2例。泊沙康唑组IFD发生率显著低于对照组(

=0.001)。泊沙康唑组一级预防38例，4例(10.5%)发生IFD；二级预防12例，2例(16.7%)发生IFD，一级预防和二级预防对IFD的发生差异无统计学意义(

=0.951)。泊沙康唑组IFD相关病死率显著低于对照组(21.0%

61.5%

=0.030)。不良反应方面，泊沙康唑组肝功异常明显少于对照组(20%

46.7%

=0.012)。

结论

泊沙康唑能更有效地预防allo-HSCT过程中IFD的发生，减少IFD相关死亡，不良反应更少。

Abstract

Objective

To investigate the efficacy and safety of posaconazole (PCZ) in the prevention of invasive fungal disease (IFD) during allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods

The medical records of 80 patients who received allo-HSCT at our center from March 2017 to March 2021 were retrospectively reviewed and analyzed. They were accordingly divided into PCZ group (

=50) and control group (

=30

taking other anti-fungal drugs). The efficacy and safety of PCZ was analyzed in the prevention of IFD.

Results

In the PCZ group

6 patients (12.0%) developed IFD

including 2 confirmed cases and 4 clinically diagnosed. While

IFD occurred in 14 cases from the control group

including 6 confirmed

6 clinically diagnosed and 2 suspected cases. The incidence of IFD was significantly lower in the PCZ group than the control group (

=0.001). Moreover

in the PCZ group

38 patients (10.5%) with primary prevention developed 4 cases of IFD

and 2 cases (16.7%) of IFD occurred in 12 patients of secondary prevention

showing no significant difference in the IFD incidence (

=0.951). The IFD-related mortality (21.0%

61.5%

=0.030) and rate of abnormal liver function (20.0%

46.7%

=0.012) were both significantly lower in the PCZ group than the control group.

Conclusion

PCZ is effective in the prevention of IFD during allo-HSCT

and reduces IFD-related deaths and occurrence of adverse reactions.

关键词

Keywords

references

JENKS J D, CORNELY O A, CHEN S C, et al . Breakthrough invasive fungal infections: Who is at risk? [J ] . Mycoses, 2020, 63(10): 1021-1032. DOI: 10.1111/myc.13148.

NEOFYTOS D, HORN D, ANAISSIE E, et al . Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungaltherapy (PATH) alliance registry[J ] . Clin Infect Dis, 2009, 48(3): 265-273. DOI: 10.1086/595846.

WINSTON D J, BARTONI K, TERRITO M C, et al . Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients[J ] . Biol Blood Marrow Transplant, 2011, 17(4): 507-515. DOI: 10.1016/j.bbmt.2010.04.017.

LIONAKIS M S, LEWIS R E, KONTOYIANNIS D P. Breakthrough invasive mold infections in the hematology patient: current concepts and future directions[J]. Clin Infect Dis, 2018, 67(10): 1621-1630. DOI: 10.1093/cid/ciy473.

MARR K A, CRIPPA F, LEISENRING W, et al . Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants[J ] . Blood, 2004, 103(4): 1527-1533. DOI: 10.1182/blood-2003-08-2644.

WINSTON D J, EMMANOUILIDES C, BARTONI K, et al . Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment[J ] . Blood, 2004, 104(5): 1581. DOI: 10.1182/blood-2004-03-1025.

ROTHE A, CLAßEN A, CARNEY J, et al . Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: a retrospective analysis[J ] . Eur J Haematol, 2020, 104(4): 291-298. DOI: 10.1111/ejh.13372.

HOF H. A new, broad-spectrum azole antifungal: posaconazole: mechanisms of action and resistance, spectrum of activity[J]. Mycoses, 2006, 49(Suppl 1): 2-6. DOI: 10.1111/j.1439-0507.2006.01295.x.

MEHTA A K, LANGSTON A A. Use of posaconazole in the treatment of invasive fungal infections[J]. Expert Rev Hematol, 2009, 2(6): 619-630. DOI: 10.1586/ehm.09.46.

CHEN L, KREKELS E H J, VERWEIJ P E, et al . Pharmacokinetics and pharmacodynamics of posaconazole[J ] . Drugs, 2020, 80(7): 671-695. DOI: 10.1007/s40265-020-01306 -y.

CORNELY O A, MAERTENS J, WINSTON D J, et al . Posaconazole vs . fluconazole or itraconazole prophylaxis in patients with neutropenia[J ] . N Engl J Med, 2007, 356(4): 348-359. DOI: 10.1056/nejmoa061094..

PAGANO L, CAIRA M, CANDONI A, et al . Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry[J ] . Clin Infect Dis, 2012, 55(11): 1515-1521. DOI: 10.1093/cid/cis773.

KRALJEVIC M, KHANNA N, MEDINGER M, et al . Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients[J ] . Med Mycol, 2021, 59(7): 701-711. DOI: 10.1093/mmy/myaa106.

SANSONE-PARSONS A, KRISHNA G, MARTINHO M, et al . Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus[J ] . Pharmacotherapy, 2007, 27(6): 825-834. DOI: 10.1592/phco.27.6.825.

COLLINS J, SHEA K, PARSAD S, et al . The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogene ic stem cell transplantation[J ] . J Oncol Pharm Pract, 2020, 26(1): 5-12. DOI: 10.1177/1078155219833440.

WONG T Y, LOO Y S, VEETTIL S K, et al . Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis[J ] . Sci Rep, 2020, 10(1): 14575. DOI: 10.1038/s41598-020-71571-0.

中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版) [J]. 中华内科杂志, 2020, 59(10): 754-763. DOI: 10.3760/cma.j.cn112138-20200627-00624.

Hematologist Branch of Chinese Medical Doctor Association, Chinese Working Group on Invasive fungal infection. Diagnostic criteria and principles of treatment for invasive mycosis in patients with hematologic diseases/malignancies (6th Revision)[J]. Chin J Internal Med, 2020, 59(10): 754-763. DOI: 10.3760/cma.j.cn112138-20200627-00624.

CHEN A P, SETSER A, ANADKAT M J, et al . Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0[J ] . J Am Acad Dermatol, 2012, 67(5): 1025-1039. DOI: 10.1016/j.jaad.2012.02.010.

VAN DAELE R, SPRIET I, MAERTENS J. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation[J]. Expert Opin Drug Metab Toxicol, 2020, 16(7): 539-550. DOI: 10.1080/17425255.2020.1764939.

TANG J L, KUNG H C, LEI W C, et al . High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan[J ] . PLoS ONE, 2015, 10(6): e0128410. DOI: 10.1371/journal.pone.0128410.

XU X H, ZHANG L, CAO X X, et al . Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China[J ] .J Infect Chemother, 2017, 23(6): 360-367. DOI: 10.1016/j.jiac.2017.02.011.

BERKING S, DOEDENS D, HORNS H, et al . Antifungal prophylaxis in newly diagnosed AML patients—Adherence to guidelines and feasibility in a real life setting[J ] . Mycoses, 2017, 60(9): 600-606. DOI: 10.1111/myc.12635.

ÖZKOCAMAN V, ÖZKALEMKAȘ F, SEYHAN S, et al . The outcome of antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: a single-center study[J ] . Turk J Haematol, 2018, 35(4): 277-282. DOI: 10.4274/tjh.2017.0430.

BUSCA A, CANDONI A, AUDISIO E, et al . Long-lasting protective effect of posaconazole prophylaxis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation[J ] . Biol Blood Marrow Transplant, 2016, 22(12): 2214-2219. DOI: 10.1016/j.bbmt.2016.09.019.

LI W, XIA F, ZHOU H, et al . Efficacy of posaconazole prophylaxis for fungal disease in hematology patients treated with chemotherapy and transplantation: an open-label, prospective, observational study[J ] . Front Microbiol, 2020, 11: 349. DOI: 10.3389/fmicb.2020.00349.

SCHRENK K G, SCHNETZKE U, STEGEMANN K, et al . Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia[J ] . J Cancer Res Clin Oncol, 2015, 141(9): 1661-1668. DOI: 10.1007/s00432-015-1962-x.

GIRMENIA C, MICOZZI A, PICIOCCHI A, et al . Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia[J ] . Leuk Res, 2014, 38(4): 469-474. DOI: 10.1016/j.leukres.2014.01.007.

KRISHNA G, MOTON A, MA L, et al . Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers[J ] . Antimicrob Agents Chemother, 2009, 53(3): 958-966. DOI: 10.1128/aac.01034-08.

CHAYAKULKEEREE M, POOVIPIROM N, SIENGWATTANA P, et al . Effect of proton pump inhibitor on plasma voriconazole concentration in thai patients[J ] . J Med Assoc Thai, 2015, 98(3): 232-237.

CHO S Y, LEE D G, CHOI S M, et al . Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in korea and clinical considerations[J ] . Mycoses, 2015, 58(9): 565-571. DOI: 10.1111/myc.12357.

AUBERGER J, LASS-FLÖRL C, AIGNER M, et al . Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study[J ] . J Antimicrob Chemother, 2012, 67(9): 2268-2273. DOI: 10.1093/jac/dks189.

BOSE P, PAREKH H D, HOLTER J L, et al . Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis[J ] . J Clin Microbiol, 2011, 49( 4): 1674-1675. DOI: 10.1128/jcm.02325-10.

LECLERC E, COMBAREL D, UZUNOV M, et al . Prevention of invasive Aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies[J ] . Sci Rep, 2018, 8(1): 1681. DOI: 10.1038/s41598-018-20136-3.

FU C C, CHEN J, XU Y, et al . Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review[J ] . Clin Investig Med, 2018, 41(1): E5-E15. DOI: 10.25011/cim.v41i1.29458.

徐宵寒, 张路, 段明辉. 评价泊沙康唑预防血液系统疾病患者粒细胞缺乏期侵袭性真菌病的效果[J]. 中国感染控制杂志, 2017, 16(1): 32-35, 57.

XU X H, ZHANG L, DUAN M H. Efficacy of posaconazole in preventing invasive fungal disease in hematologic patients with neutropenia[J]. Chin J Infect Control, 2017, 16(1): 32-35, 57.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Improvement of hematopoietic stem cell transplantation in the targeted therapy era

Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation

Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center

Effect and mechanism of human umbilical cord mesenchymal stem cells on preventing murine acute graft-versus-host disease

A combined strategy of surface markers for sorting immune cell subsets in patients with chronic graft-versus-host disease

Related Author

Xi ZHANG

Ruihao HUANG

Cong ZENG

Xu CHEN

Juan HUA

Tingting CHENG

Xia MA

Yajing XU

Related Institution

State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Hematology, Xiangya Hospital, Central South University

Department of Clinical Laboratory, the Second Affiliated Hospital of Zunyi Medical University

Department of Cell Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University)

Department of Hematology, the First Affiliated Hospital of Chongqing Medical University

⁰